Fintel reports that on October 16, 2023, Cantor Fitzgerald maintained coverage of Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral recommendation.
Analyst Price Forecast Suggests 49.92% Upside
As of October 5, 2023, the average one-year price target for Alnylam Pharmaceuticals is 250.74. The forecasts range from a low of 135.34 to a high of $425.25. The average price target represents an increase of 49.92% from its latest reported closing price of 167.25.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Alnylam Pharmaceuticals is 1,521MM, an increase of 22.92%. The projected annual non-GAAP EPS is -5.74.
What is the Fund Sentiment?
There are 1016 funds or institutions reporting positions in Alnylam Pharmaceuticals. This is a decrease of 7 owner(s) or 0.68% in the last quarter. Average portfolio weight of all funds dedicated to ALNY is 0.31%, a decrease of 10.04%. Total shares owned by institutions increased in the last three months by 0.26% to 144,943K shares. 
The put/call ratio of ALNY is 1.22, indicating a bearish outlook.
What are Other Shareholders Doing?
Capital World Investors holds 16,498K shares representing 13.20% ownership of the company. In it's prior filing, the firm reported owning 16,476K shares, representing an increase of 0.13%. The firm decreased its portfolio allocation in ALNY by 11.65% over the last quarter.
Baillie Gifford holds 8,392K shares representing 6.71% ownership of the company. In it's prior filing, the firm reported owning 8,639K shares, representing a decrease of 2.94%. The firm decreased its portfolio allocation in ALNY by 13.22% over the last quarter.
AGTHX - GROWTH FUND OF AMERICA holds 7,929K shares representing 6.34% ownership of the company. In it's prior filing, the firm reported owning 7,572K shares, representing an increase of 4.50%. The firm decreased its portfolio allocation in ALNY by 3.93% over the last quarter.
Wellington Management Group Llp holds 6,068K shares representing 4.85% ownership of the company. In it's prior filing, the firm reported owning 6,154K shares, representing a decrease of 1.42%. The firm decreased its portfolio allocation in ALNY by 10.78% over the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 4,719K shares representing 3.77% ownership of the company. No change in the last quarter.
Alnylam Pharmaceuticals Background Information
(This description is provided by the company.)
Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
